NeuroOne Medical Technologies Corporation Receives FDA 510(k) Clearance for Evo Cortical Electrode The Company believes that the Evo Cortical Electrode is the first cortical electrode to receive FDA 510(k) clearance that

NeuroOne Medical Technologies

Corporation Receives FDA 510(k) Clearance for Evo Cortical Electrode

The Company believes that the

Evo Cortical Electrode is the first cortical electrode to receive FDA 510(k) clearance that uses thin film printed

microcircuit technology manufactured using a fully automated photolithographic process

Eden Prairie, MN - December

2, 2019 - NeuroOne Medical Technologies Corporation (OTCQB: NMTC), a medical

device company focused on the development and commercialization of thin film electrode technology for recording brain activity,

stimulation and ablation solutions for patients suffering from Epilepsy, Parkinson's Disease, and back pain, today announced that

it has received U.S. Food and Drug Administration (FDA) 510(k) clearance to market its thin film cortical electrode technology

for temporary (less than 30 days) recording, monitoring, and stimulation on the surface of the brain.

Evo Cortical Electrode product line is the result of a collaboration with both Wisconsin Alumni Research Foundation and Mayo

Foundation for Medical Education and Research. This thin film technology offers the potential for improved resolution during

recording brain activity, future placement through a less invasive procedure, and reduced inflammation of brain tissue as demonstrated

in testing conducted at the Mayo Clinic.

is certainly a monumental achievement for the Company," stated Dave Rosa, NeuroOne's President and CEO. "A great

deal of work, perseverance and commitment from our employees, development partners, consultants and manufacturing partners made

this possible. This 510(k) clearance is a critical step in executing our corporate strategy, and we look forward to working towards

our goal of applying this platform to a variety of other devices for recording, monitoring and stimulation for various therapeutic

applications such as epilepsy, Parkinson's Disease, spinal cord stimulation and artificial intelligence."

NeuroOne Medical Technologies Corporation

is a developmental stage company committed to providing minimally invasive and hi-definition solutions for EEG recording, brain

stimulation and ablation solutions for patients suffering from Epilepsy, Parkinson's Disease, Essential Tremors and other

related neurological disorders that may improve patient outcomes and reduce procedural costs.

Forward Looking Statement

This press release may include forward-looking

statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange

Act of 1934, as amended. Except for statements of historical fact, any information contained in this presentation may be a forward-looking

statement that reflects the Company's current views about future events and are subject to known and unknown risks, uncertainties

and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different

from the information expressed or implied by these forward-looking statements. In some cases, you can identify forward-looking

statements by the words "may," "might," "will," "could," "would,"

"should," "expect," "intend," "plan," "objective," "anticipate,"

"believe," "estimate," "predict," "project," "potential," "target,"

"seek," "contemplate," "continue" and "ongoing," or the negative of these terms,

or other comparable terminology intended to identify statements about the future. Forward-looking statements may include statements

regarding the Company's regulatory submissions, potential regulatory approval, commercialization of the technology, business

strategy, market size, potential growth opportunities, plans for product applications and product development, future operations,

future efficiencies, and other financial and operating information. Although the Company believes that we have a reasonable basis

for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently

known by us and our expectations of the future, about which we cannot be certain. Our actual future results may be materially

different from what we expect due to factors largely outside our control, including our ability to raise additional funds, uncertainties

inherent in the development process of our technology, changes in regulatory requirements or decisions of regulatory authorities,

the size and growth potential of the markets for our technology, our ability to serve those markets, the rate and degree of market

acceptance of our products, clinical trial patient enrollment, the results of clinical trials, future competition, the actions

of third-party clinical research organizations, suppliers and manufacturers, our ability to protect our intellectual property

rights and other risks, uncertainties and assumptions, including those described under the heading "Risk Factors"

in our filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this

press release and the Company undertakes no obligation to revise or update any forward-looking statements for any reason, even

if new information becomes available in the future.

Investor Relations Contact:

Sr. Director of Marketing

NeuroOne Medical Technologies Corporation

law restricts this device to sale by or on the order of a physician"